Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma

NCT02102022 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Gastrointestinal (GI) Malignancies
Hepatocellular Carcinoma
Gastric Cancer
Colorectal Cancer

Interventions

DRUG: ADI-PEG 20 plus modified FOLFOX6

Sponsor

Polaris Group